NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘OrbiMed’

24 May 2016

OrbiMed raises $307m for second Israel-focused fund

doctor-563428_1280 OrbiMed, an investment firm focused on the healthcare sector, has launched a $307m Israel-focused venture capital fund.

11 January 2016

Biopharmaceutical company Zai Lab raises $100m from VCs in Series B round

pillbox-1013220_1280 China-based biopharmaceutical company Zai Lab has received $100m from venture capital investors in a Series B financing round led by Advantech Capital.

16 December 2015

OrbiMed sets $300m target for second Israel-dedicated fund

Global healthcare investor OrbiMed has launched fundraising for its second vehicle focused on Israel's life sciences market, targeting $300m.

24 November 2015

Serious pregnancy condition drug developer nabs CHF60m VC-backed Series B

pregnant-244662_1920 Swiss biopharmaceutical company ObsEva, which develops drugs focusing on serious conditions compromising pregnancy, has raised a CHF60m ($59m) Series B round from a string of venture capital firms.

10 April 2015

Antibiotics researcher Nabriva gets $120m Vivo Capital, OrbiMed-led Series B

Nabriva Antibiotics research pioneer Nabriva Therapeutics has picked up a huge $120m Series B round from investors including Vivo Capital and OrbiMed.

4 March 2015

OrbiMed leads weighty $30m round in biopharmaceutical company Tricida

download (65) Venture capital firm OrbiMed has led a $30m Series B financing round in San Francisco-based biopharmaceutical company Tricida.

3 February 2015

OrbiMed closes Royalty Opportunities II on $924m

heart monitor medical healthcare Venture capital firm OrbiMed has closed its second healthcare royalty and credit opportunities Fund on $924m, AltAssets can reveal.

9 January 2015

OrbiMed, Janus join $51.4m Series D for cancer-fighting Aduro Biotech

syringe-m Venture capital investors Orbimed and Janus Capital Management are among new investors backing a hefty $51.4m Series D round of financing for cancer-researching biotech company Aduro Biotech.

3 December 2014

Venture-backed gene therapy business Audentes nets $42.5m Series B

Audentes A string of venture capital firms have taken part in a $42.5m Series B financing round for gene therapy business Audentes Therapeutics.

1 December 2014

Growth hormone deficiency treatment company Ascendis picks up $60m VC-backed Series D

drug tablet pill medical pharma Sofinnova Ventures has joined with OrbiMed and Vivo Capital to lead a $60m Series D financing round for biotech business Ascendis Pharma.

Page 1 of 3123

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016